Pyxis Oncology Inc (PYXS)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.68-1.75%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Pyxis Oncology Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	25,000
EPS	—	-0.258
Annual ending 2026-12-31
Revenue	—	21,875
EPS	—	-1.213
Annual ending 2027-12-31
Revenue	—	3.13M
EPS	—	-1.108

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Extend cash runway into Q4 2026	It aims to extend cash into Q4 2026.	Intact	Cash runway does not extend into Q4 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance MICVO development for head and neck cancer	Pyxis is developing a new cancer drug called MICVO.	Improving	Development of MICVO stalls or fails to advance	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stabilize or grow revenue after expected decline	A supporting condition in Pyxis Oncology Inc's published investment case. The stated target is Revenue growth better than -18% in next 12 months.	Intact	Revenue declines worse than -18% over next year	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.11

$-1.21 → $-1.11 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.21	$4,166,667	6 / 8
2026-07-25	$-1.21	$4,166,667	6 / 8
2026-07-26	$-1.21	$4,166,667	6 / 8
2026-07-27	$-1.21	$4,166,667	6 / 8
2026-07-28	$-1.21	$4,166,667	6 / 8
2026-07-29	$-1.21	$4,166,667	6 / 8
2026-07-30	$-1.21	$4,166,667	6 / 8
2026-07-31	$-1.21	$4,166,667	6 / 8
2026-08-01	$-1.21	$4,166,667	6 / 8
2026-08-02	$-1.21	$3,125,000	8 / 8
2026-08-03	$-1.21	$4,166,667	6 / 8
2026-08-04	$-1.21	$3,125,000	8 / 8
2026-08-05	$-1.21	$3,125,000	8 / 8
2026-08-06	$-1.21	$4,166,667	6 / 8
2026-08-07	$-1.21	$4,166,667	6 / 8
2026-08-08	$-1.20	$2,777,780	9 / 9
2026-08-09	$-1.21	$4,166,667	6 / 8
2026-08-10	$-1.20	$2,777,780	9 / 9
2026-08-12	$-1.20	$2,777,780	9 / 9
2026-08-13	$-1.21	$4,166,667	6 / 8
2026-08-14	$-1.21	$4,166,667	6 / 8
2026-08-15	$-1.21	$4,166,667	6 / 8
2026-08-16	$-1.21	$4,166,667	6 / 8
2026-08-17	$-1.21	$4,166,667	6 / 8
2026-08-18	$-1.21	$4,166,667	6 / 8
2026-08-19	$-1.21	$4,166,667	6 / 8
2026-08-20	$-1.13	$3,125,000	6 / 9
2026-08-21	$-1.13	$3,125,000	6 / 9
2026-08-22	$-1.13	$3,125,000	6 / 9
2026-08-23	$-1.13	$3,125,000	6 / 9
2026-08-24	$-1.13	$3,125,000	6 / 9
2026-08-25	$-1.13	$3,125,000	6 / 9
2026-08-26	$-1.13	$3,125,000	6 / 9
2026-08-27	$-1.13	$3,125,000	6 / 9
2026-08-28	$-1.13	$3,125,000	6 / 9
2026-08-29	$-1.13	$3,125,000	6 / 9
2026-08-30	$-1.13	$3,125,000	6 / 9
2026-08-31	$-1.13	$3,125,000	6 / 9
2026-09-01	$-1.13	$3,125,000	6 / 9
2026-09-02	$-1.13	$3,125,000	6 / 9
2026-09-03	$-1.13	$3,125,000	6 / 9
2026-09-04	$-1.13	$3,125,000	6 / 9
2026-09-05	$-1.13	$3,125,000	6 / 9
2026-09-06	$-1.13	$3,125,000	6 / 9
2026-09-07	$-1.13	$3,125,000	6 / 9
2026-09-08	$-1.13	$3,125,000	6 / 9
2026-09-09	$-1.13	$3,125,000	6 / 9
2026-09-10	$-1.13	$3,125,000	6 / 9
2026-09-11	$-1.13	$3,125,000	6 / 9
2026-09-12	$-1.13	$3,125,000	6 / 9
2026-09-13	$-1.13	$3,125,000	6 / 9
2026-09-14	$-1.13	$3,125,000	6 / 9
2026-09-15	$-1.13	$3,125,000	6 / 9
2026-09-16	$-1.13	$3,125,000	6 / 9
2026-09-17	$-1.13	$3,125,000	6 / 9
2026-09-18	$-1.13	$3,125,000	6 / 9
2026-09-19	$-1.13	$3,125,000	6 / 9
2026-09-20	$-1.13	$3,125,000	6 / 9
2026-09-21	$-1.13	$3,125,000	6 / 9
2026-09-22	$-1.13	$3,125,000	6 / 9
2026-09-23	$-1.13	$3,125,000	6 / 9
2026-09-24	$-1.13	$3,125,000	6 / 9
2026-09-25	$-1.13	$3,125,000	6 / 9
2026-09-26	$-1.13	$3,125,000	6 / 9
2026-09-27	$-1.13	$3,125,000	6 / 9
2026-09-28	$-1.13	$3,125,000	6 / 9
2026-09-29	$-1.13	$3,125,000	6 / 9
2026-09-30	$-1.13	$3,125,000	6 / 9
2026-10-01	$-1.13	$3,125,000	6 / 9
2026-10-02	$-1.13	$3,125,000	6 / 9
2026-10-03	$-1.13	$3,125,000	6 / 9
2026-10-04	$-1.13	$3,125,000	6 / 9
2026-10-05	$-1.13	$3,125,000	6 / 9
2026-10-06	$-1.13	$3,125,000	6 / 9
2026-10-07	$-1.13	$3,125,000	6 / 9
2026-10-08	$-1.13	$3,125,000	6 / 9
2026-10-09	$-1.11	$3,125,000	6 / 9
2026-10-10	$-1.11	$3,125,000	6 / 9
2026-10-11	$-1.11	$3,125,000	6 / 9
2026-10-12	$-1.11	$3,125,000	6 / 9
2026-10-13	$-1.11	$3,125,000	6 / 9
2026-10-14	$-1.11	$3,125,000	6 / 9
2026-10-15	$-1.11	$3,125,000	6 / 9
2026-10-16	$-1.11	$3,125,000	6 / 9
2026-10-17	$-1.11	$3,125,000	6 / 9
2026-10-18	$-1.11	$3,125,000	6 / 9
2026-10-19	$-1.11	$3,125,000	6 / 9
2026-10-20	$-1.11	$3,125,000	6 / 9
2026-10-21	$-1.11	$3,125,000	6 / 9
2026-10-22	$-1.11	$3,125,000	6 / 9
2026-10-23	$-1.11	$3,125,000	6 / 9
2026-10-24	$-1.11	$3,125,000	6 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	9	1
2026-06-01	9	1
2026-07-01	8	1
2026-08-01	9	1
2026-09-01	9	1
2026-10-01	9	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Extend cash runway into Q4 2026Direct metric needs a verified mapping
Advance MICVO development for head and neck cancerDirect metric needs a verified mapping
Stabilize or grow revenue after expected declineDirect metric needs a verified mapping

Next proof point

Nov 2, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

4.3%Typical daily move · historical

Downside history

-56.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Pyxis Oncology Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established compounder: earnings are negative and recent financial performance is weak. The long-term thesis is in a watch state, with low overall confidence and mixed progress on management priorities.

What's priced into Pyxis Oncology Inc

The evidence tags pricing as justified, with low fragility, but the expectations gap is negative. That suggests the market case does not leave much room for weaker-than-expected execution, though the snapshot provides no peer comparison to judge whether the valuation is cheap, fair, or expensive.

What the fundamentals likely do

Near term, operating results are likely to remain pressured by clinical development costs, and the evidence flags elevated risk of an earnings miss. Management has reported positive Phase 1 MICVO data and extended cash runway into Q2 2027, but expense control has been mixed and performance remains below the industry cohort.

What Pyxis Oncology Inc hinges on

Over the next few years, the central swing factor is whether MICVO advances toward the planned Phase 3 start in mid-2027 and produces further useful data. Near-term guidance cuts, a weaker jobs trend, or continued cash and expense pressure would weaken the case; stronger healthcare-sector results could provide a more supportive backdrop.